Literature DB >> 29380258

The Influence of Patient-Reported Joint Manifestations on Quality of Life in Fabry Patients.

Alexandra Ivleva1, Ekaterina Weith2, Atul Mehta3,4, Derralynn A Hughes5,6,7.   

Abstract

Fabry disease, a lysosomal storage disorder, is a rare inborn error of metabolism caused by deficiency of the enzyme alpha galactosidase A and resulting accumulation of globotriaosylceramide. The symptoms of Fabry disease are heterogeneous including renal failure, cardiac hypertrophy, and stroke and may not be well recognized by non-specialist physicians. Patients with milder, later onset of disease often have a delay in diagnosis.Fabry patients may suffer significant neuropathic pain in the extremities (acroparasthesia) but the degree to which musculoskeletal symptoms contribute to total pain and disability is unknown. Here, we present a questionnaire study focusing on joint manifestations and their impact on daily life of patients with Fabry disease.Seventy-seven patients with Fabry disease and age-matched healthy controls (49 female and 28 male) took part in a survey focused on joint problems, pain, disability, and quality of life. Joint pain and swelling were reported by 43% of male and 39% of female Fabry patients. Analysis by age group showed higher prevalence of joint problems and decreased quality of life, in terms of mobility, activity, pain, and anxiety, in Fabry patients younger than 50 years compared to healthy controls. Female Fabry patients had higher fatigue scores compared to control subjects. Fabry patients reported problems with vigorous daily activities and gripping.Musculoskeletal symptoms are common in Fabry patients and contribute to overall pain and decreased quality of life. Awareness of Fabry disease by physicians may be raised to ensure timely diagnosis of this rare disease.

Entities:  

Keywords:  Fabry disease; Joints manifestations; Lysosomal storage disorder; Multidisciplinary team-care; Musculoskeletal symptoms; Patient-reported outcomes

Year:  2018        PMID: 29380258      PMCID: PMC6122052          DOI: 10.1007/8904_2017_84

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  32 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

Review 2.  Anderson-Fabry disease: extrarenal, neurologic manifestations.

Authors:  Edwin H Kolodny; Gregory M Pastores
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

3.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

Review 4.  Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2005-04

5.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

6.  Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density.

Authors:  Henriette Mersebach; Jan-Ove Johansson; Ase Krogh Rasmussen; Bengt-Ake Bengtsson; Kirsten Rosenberg; Lis Hasholt; Sven Asger Sørensen; Søren Schwartz Sørensen; Ulla Feldt-Rasmussen
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

7.  Joint manifestations of Fabry's disease.

Authors:  S O Paira; S Roverano; J L Iribas; H A Barceló
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

9.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

10.  Association of Fabry's disease with femoral head avascular necrosis.

Authors:  G Ross; F Kuwamura; A Goral
Journal:  Orthopedics       Date:  1993-04       Impact factor: 1.390

View more
  4 in total

1.  Stratification of patients with unclassified pain in the FabryScan database.

Authors:  Julia Forstenpointner; Paul Moeller; Manon Sendel; Maren Reimer; Philipp Hüllemann; Ralf Baron
Journal:  J Pain Res       Date:  2019-07-23       Impact factor: 3.133

2.  Shared decision making between patients with Fabry disease and physicians in Japan: An online survey.

Authors:  Natsuko Inagaki; Mio Tsuchiya; Kazuki Otani; Takeo Nakayama
Journal:  Mol Genet Metab Rep       Date:  2022-08-10

3.  Quality of life in patients with Fabry's disease: a cross-sectional study of 86 adults.

Authors:  Caroline Andonian; Jürgen Beckmann; Oliver Mayer; Peter Ewert; Annika Freiberger; Maximilian Huber; Harald Kaemmerer; Christine Kurschat; Florian Lagler; Nicole Nagdyman; Lars Pieper; Claudia Regenbogen; Sebastian Freilinger
Journal:  Cardiovasc Diagn Ther       Date:  2022-08

4.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.